The Good News for Biotech: New Regulation Opens A New Path to Profitability
This article was originally published in The Pink Sheet Daily
Executive Summary
REMS program may create new options for smaller companies targeting niche markets.
You may also be interested in...
GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?